首页 > 最新文献

Transplantation Reviews最新文献

英文 中文
Cutaneous squamous cell carcinoma in solid organ transplant recipients: Current therapeutic and screening strategies 实体器官移植受者的皮肤鳞状细胞癌:当前的治疗和筛查策略。
IF 3.6 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-09-25 DOI: 10.1016/j.trre.2024.100882
Solid organ transplant recipients (SOTRs) are particularly prone to developing malignancies, often manifesting multiple tumors and tumors with a heightened susceptibility to metastasis, resulting in much lower survival rates when compared to the general population. Among these, cutaneous squamous cell carcinoma (CSCC) respresent a major challenge in terms of morbidity and mortality following organ transplantation. The management of post-transplant CSCC requires expertise from various disciplines, including dermatology, maxillofacial surgery, transplant medicine, radiation oncology, and medical oncology. Furthermore, the unique behaviors and prevalence of tumors in SOTRs necessitate tailored pathways for screening and treatment, distinct from those designed for immunocompetent patients. Despite the proven efficacy of immune checkpoint inhibitors (ICIs) in several cancers, SOTRs have often been systematically excluded from clinical trials due to concerns about potential allograft rejection and loss. Consequently, most data on the safety and efficacy of ICIs in SOTRs are derived from case series and reports. Given the significant risks involved, alternative therapeutic options should be thoroughly discussed with patients before considering ICI therapy. This literature review aims to provide an overview of CSCC in SOTRs, with a specific emphasis on therapeutic and screening strategies, particularly highlighting immunotherapy.
实体器官移植受者(SOTRs)特别容易罹患恶性肿瘤,通常表现为多种肿瘤和易转移的肿瘤,导致生存率远低于普通人群。其中,皮肤鳞状细胞癌(CSCC)是器官移植后发病率和死亡率方面的一大挑战。移植后 CSCC 的治疗需要皮肤科、颌面外科、移植内科、放射肿瘤科和肿瘤内科等多个学科的专业知识。此外,SOTRs 中肿瘤的独特行为和发病率使得筛查和治疗的路径必须有别于为免疫功能正常患者设计的路径。尽管免疫检查点抑制剂(ICIs)在多种癌症中的疗效已得到证实,但由于担心潜在的异体移植排斥反应和损失,SOTR 往往被系统性地排除在临床试验之外。因此,有关 ICIs 在 SOTR 中安全性和有效性的大多数数据都来自病例系列和报告。考虑到所涉及的重大风险,在考虑使用 ICI 治疗之前,应与患者充分讨论其他治疗方案。这篇文献综述旨在概述SOTRs中的CSCC,特别强调了治疗和筛查策略,尤其突出了免疫疗法。
{"title":"Cutaneous squamous cell carcinoma in solid organ transplant recipients: Current therapeutic and screening strategies","authors":"","doi":"10.1016/j.trre.2024.100882","DOIUrl":"10.1016/j.trre.2024.100882","url":null,"abstract":"<div><div>Solid organ transplant recipients (SOTRs) are particularly prone to developing malignancies, often manifesting multiple tumors and tumors with a heightened susceptibility to metastasis, resulting in much lower survival rates when compared to the general population. Among these, cutaneous squamous cell carcinoma (CSCC) respresent a major challenge in terms of morbidity and mortality following organ transplantation. The management of post-transplant CSCC requires expertise from various disciplines, including dermatology, maxillofacial surgery, transplant medicine, radiation oncology, and medical oncology. Furthermore, the unique behaviors and prevalence of tumors in SOTRs necessitate tailored pathways for screening and treatment, distinct from those designed for immunocompetent patients. Despite the proven efficacy of immune checkpoint inhibitors (ICIs) in several cancers, SOTRs have often been systematically excluded from clinical trials due to concerns about potential allograft rejection and loss. Consequently, most data on the safety and efficacy of ICIs in SOTRs are derived from case series and reports. Given the significant risks involved, alternative therapeutic options should be thoroughly discussed with patients before considering ICI therapy. This literature review aims to provide an overview of CSCC in SOTRs, with a specific emphasis on therapeutic and screening strategies, particularly highlighting immunotherapy.</div></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142335637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors and interventions affecting tacrolimus intrapatient variability: A systematic review and meta-analysis 影响他克莫司患者间变异性的因素和干预措施:系统回顾和荟萃分析
IF 3.6 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-09-07 DOI: 10.1016/j.trre.2024.100878

Backgrounds

Tacrolimus is a cornerstone of posttransplantation immunosuppressive regimens. Despite routine monitoring, the efficacy of its trough concentrations in reflecting drug concentration fluctuations is limited. Intrapatient variability (IPV) emerges as a novel monitoring marker for predicting clinical outcomes. However, understanding the factors affecting IPV and assessing interventions to address it remain enigmatic, posing a conundrum in clinical management.

Objectives

This systematic review aimed to investigate a spectrum of factors affecting IPV and assess the effect of strategic interventions, thereby charting a course for enhanced clinical stewardship.

Methods

We electronically searched of PubMed, Embase, and the Cochrane Library databases for studies investigating factors and interventions affecting IPV up to October 2023. Two reviewers independently screened literature, extracted data, and assessed quality, using RevMan 5.4.1 software for meta-analysis.

Results

A total of 15 randomized controlled trials (RCTs), 34 cohort studies, and 20 self-controlled studies were included. The results indicated that IPV was significantly higher in cytochrome P450 3A5 (CYP3A5) expressers, nonadherent patients, patients taking proton pump inhibitors or statins, and Black or African American recipients, whereas recipients consuming extended-release formulation exhibited lower IPV. Additionally, the participation of pharmacists had a positive effect on improving IPV.

Conclusions

Factors affecting IPV encompassed genotype, formulation, adherence, drug combinations, and ethnicity, with each factor exerting varying degrees of effect. Identifying these factors was crucial for developing targeted intervention strategies. While the participation of pharmacists held a promise in improving IPV, further investigation of interventions such as mobile technology, educational measures to enhance adherence, and personalized dosing regimens was warranted.

背景他克莫司是移植后免疫抑制疗法的基石。尽管进行了常规监测,但其谷浓度在反映药物浓度波动方面的效果有限。患者体内变异性(IPV)成为预测临床结果的新型监测指标。本系统综述旨在研究影响 IPV 的一系列因素,并评估战略性干预措施的效果,从而为加强临床管理指明方向。方法我们以电子方式检索了 PubMed、Embase 和 Cochrane Library 数据库中截至 2023 年 10 月有关影响 IPV 的因素和干预措施的研究。结果共纳入 15 项随机对照试验 (RCT)、34 项队列研究和 20 项自我对照研究。结果表明,细胞色素 P450 3A5 (CYP3A5) 表达者、不依从性患者、服用质子泵抑制剂或他汀类药物的患者以及黑人或非裔美国人受者的 IPV 明显较高,而服用缓释制剂的受者的 IPV 较低。结论影响 IPV 的因素包括基因型、制剂、依从性、药物组合和种族,每个因素都会产生不同程度的影响。确定这些因素对于制定有针对性的干预策略至关重要。虽然药剂师的参与有望改善 IPV,但仍有必要进一步研究移动技术、提高依从性的教育措施和个性化给药方案等干预措施。
{"title":"Factors and interventions affecting tacrolimus intrapatient variability: A systematic review and meta-analysis","authors":"","doi":"10.1016/j.trre.2024.100878","DOIUrl":"10.1016/j.trre.2024.100878","url":null,"abstract":"<div><h3>Backgrounds</h3><p>Tacrolimus is a cornerstone of posttransplantation immunosuppressive regimens. Despite routine monitoring, the efficacy of its trough concentrations in reflecting drug concentration fluctuations is limited. Intrapatient variability (IPV) emerges as a novel monitoring marker for predicting clinical outcomes. However, understanding the factors affecting IPV and assessing interventions to address it remain enigmatic, posing a conundrum in clinical management.</p></div><div><h3>Objectives</h3><p>This systematic review aimed to investigate a spectrum of factors affecting IPV and assess the effect of strategic interventions, thereby charting a course for enhanced clinical stewardship.</p></div><div><h3>Methods</h3><p>We electronically searched of PubMed, Embase, and the Cochrane Library databases for studies investigating factors and interventions affecting IPV up to October 2023. Two reviewers independently screened literature, extracted data, and assessed quality, using RevMan 5.4.1 software for meta-analysis.</p></div><div><h3>Results</h3><p>A total of 15 randomized controlled trials (RCTs), 34 cohort studies, and 20 self-controlled studies were included. The results indicated that IPV was significantly higher in cytochrome P450 3A5 (<em>CYP3A5</em>) expressers, nonadherent patients, patients taking proton pump inhibitors or statins, and Black or African American recipients, whereas recipients consuming extended-release formulation exhibited lower IPV. Additionally, the participation of pharmacists had a positive effect on improving IPV.</p></div><div><h3>Conclusions</h3><p>Factors affecting IPV encompassed genotype, formulation, adherence, drug combinations, and ethnicity, with each factor exerting varying degrees of effect. Identifying these factors was crucial for developing targeted intervention strategies. While the participation of pharmacists held a promise in improving IPV, further investigation of interventions such as mobile technology, educational measures to enhance adherence, and personalized dosing regimens was warranted.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142164555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value of single photon emission computed tomography myocardial perfusion imaging for the prediction of MACE in pre- kidney transplant recipients: A systematic review and meta-analysis 单光子发射计算机断层扫描心肌灌注成像在预测肾移植前受者 MACE 方面的预后价值:系统回顾和荟萃分析
IF 3.6 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-08-22 DOI: 10.1016/j.trre.2024.100879

Background

Kidney transplantation provides substantial benefits in extending survival and improving quality of life for patients with end-stage renal disease. The incidence of major adverse cardiac events (MACE) increases with a decline of kidney function in patients with chronic kidney disease. After kidney transplantation, the incidence of MACE remains high. The objective of this study was to assess the prognostic significance of pre-transplant single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) in kidney transplant recipients.

Methods

A systematic literature search was performed between January 1st 2015 and March 26th 2024 in PubMed, EMBASE, Web of Science and The Cochrane Library to identify the prognostic value of SPECT MPI for developing MACE (primary outcome) and mortality (secondary outcome) in kidney transplant recipients (PROSPERO CRD42020188610). Risk of bias was assessed. Meta-analyses and subgroup analyses were performed using random-effects models.

Results

Six studies comprising 2090 SPECT MPI scans were included. Abnormal SPECT MPI scans were associated with an increased risk of MACE post-transplantation (HR 1.62, 95% CI 1.27–2.06, p < 0.001). Subgroup analyses showed consistent findings across various patient populations and methodological differences. Sensitivity analyses supported the robustness of our findings.

Conclusions

Current evidence showed that pre-transplant SPECT MPI has significant prognostic value in identifying kidney transplant candidates at risk for MACE post-transplantation. Integrating SPECT MPI into preoperative assessments might enhance risk stratification and guide clinical decision-making. Prospective studies are needed to refine risk prediction models.

背景肾移植为终末期肾病患者延长生存期和改善生活质量带来了巨大益处。随着慢性肾脏病患者肾功能的下降,主要心脏不良事件(MACE)的发生率也随之增加。肾移植后,MACE 的发生率仍然很高。本研究旨在评估肾移植受者移植前单光子发射计算机断层扫描(SPECT)心肌灌注成像(MPI)的预后意义。方法2015年1月1日至2024年3月26日期间,在PubMed、EMBASE、Web of Science和The Cochrane Library进行了系统性文献检索,以确定SPECT MPI对肾移植受者发生MACE(主要结局)和死亡率(次要结局)的预后价值(PROSPERO CRD42020188610)。评估了偏倚风险。结果纳入了六项研究,共进行了 2090 次 SPECT MPI 扫描。SPECT MPI扫描异常与移植后MACE风险增加有关(HR 1.62,95% CI 1.27-2.06,p <0.001)。亚组分析表明,不同患者群体和方法差异的研究结果是一致的。结论目前的证据显示,移植前 SPECT MPI 在确定移植后有 MACE 风险的肾移植候选者方面具有显著的预后价值。将 SPECT MPI 纳入术前评估可加强风险分层并指导临床决策。需要进行前瞻性研究以完善风险预测模型。
{"title":"Prognostic value of single photon emission computed tomography myocardial perfusion imaging for the prediction of MACE in pre- kidney transplant recipients: A systematic review and meta-analysis","authors":"","doi":"10.1016/j.trre.2024.100879","DOIUrl":"10.1016/j.trre.2024.100879","url":null,"abstract":"<div><h3>Background</h3><p>Kidney transplantation provides substantial benefits in extending survival and improving quality of life for patients with end-stage renal disease. The incidence of major adverse cardiac events (MACE) increases with a decline of kidney function in patients with chronic kidney disease. After kidney transplantation, the incidence of MACE remains high. The objective of this study was to assess the prognostic significance of pre-transplant single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) in kidney transplant recipients.</p></div><div><h3>Methods</h3><p>A systematic literature search was performed between January 1st 2015 and March 26th 2024 in PubMed, EMBASE, Web of Science and The Cochrane Library to identify the prognostic value of SPECT MPI for developing MACE (primary outcome) and mortality (secondary outcome) in kidney transplant recipients (PROSPERO CRD42020188610). Risk of bias was assessed. Meta-analyses and subgroup analyses were performed using random-effects models.</p></div><div><h3>Results</h3><p>Six studies comprising 2090 SPECT MPI scans were included. Abnormal SPECT MPI scans were associated with an increased risk of MACE post-transplantation (HR 1.62, 95% CI 1.27–2.06, <em>p</em> &lt; 0.001). Subgroup analyses showed consistent findings across various patient populations and methodological differences. Sensitivity analyses supported the robustness of our findings.</p></div><div><h3>Conclusions</h3><p>Current evidence showed that pre-transplant SPECT MPI has significant prognostic value in identifying kidney transplant candidates at risk for MACE post-transplantation. Integrating SPECT MPI into preoperative assessments might enhance risk stratification and guide clinical decision-making. Prospective studies are needed to refine risk prediction models.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0955470X24000624/pdfft?md5=6c04c0c5206bc922b0ec873e612c3ebb&pid=1-s2.0-S0955470X24000624-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142135113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maribavir treatment for resistant cytomegalovirus disseminated disease in kidney transplant recipients: A case-based scoping review of real life data in literature 肾移植受者耐药巨细胞病毒播散性疾病的马利巴韦治疗:基于病例的文献真实数据范围综述
IF 3.6 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-08-21 DOI: 10.1016/j.trre.2024.100873

The treatment of refractory CMV is often associated with high toxicity. Maribavir (MBV) is a novel oral antiviral, known for its favourable safety profile in fragile patients. We describe a case of CMV disease with end organ damage following kidney transplantation at high risk, for recipient-donor serological mismatch. A 54-year-old female with history of obesity, hypertension, and chronic kidney disease, on prednisone and tacrolimus after kidney transplantation in November 2022, soon after developed primary CMV infection, treated with Valganciclovir and CMV Ig. In January 2023 the patient presented with fever and dyspnea. Pulmonary miliary opacities and right-upper lobe consolidation were found at CT-scan along with CMV-DNA positivity on BAL and serum. Lung biopsy confirmed CMV infection. Antiviral was switched to Ganciclovir. Despite initial benefit, fever and respiratory failure happened 8 days later, leading to intubation at day 15. Due to slow decrease serum CMV-DNA and detection of UL97 mutation, conferring resistance to valganciclovir and ganciclovir, the patient was started on foscarnet and letermovir. She was extubated after a gradual respiratory improvement and discharged from ICU to rehabilitation department with HFNC; reduction in serum CMV-DNA, but persistently elevated CMV-DNA on BAL were documented. At week 8, MBV was started and letermovir continued, for a 8 weeks course, without notable adverse effects. Respiratory function improved but soon after septic shock occurred. A bone marrow biopsy resulted in lymphoma, without indications for treatment: the patient developed coma and died 6 months after admission. MBV has recently been approved in Europe for treatment of R/R CMV in HSCT and SOT recipients. MBV showed superior rates of viraemia clearance after 8 weeks compared to SOC, demonstrating also a favourable safety profile with fewer patients discontinuing treatment and being affected by nephrotoxicity and neutropenia. Its main side effects are taste impairment, gastro-intestinal symptoms and asthenia. Based on actual promising perspectives regarding antiviral stewardship, more data are required to corroborate benefit of MBV in terms of toxicity and impact on mortality in highly fragile populations as SOT recipients.

MBV received approval for the treatment of refractory or resistant CMV infections to other antiviral agents. Nevertheless, real-life data on efficacy and safety of MBV are still lacking.

We conducted a narrative review of the current literature on MBV as treatment for CMV infection in kidney transplant recipients to understand clinical characteristics, safety and outcomes of MBV in this population. A search was run on the main scientific databases. 194 papers were identified, of which 188 were excluded by title and abstract evaluation. Subsequently, 6 papers were included. We performed descriptive statistics on the entire study population. The studies included in our analysis showed a higher preva

治疗难治性巨细胞病毒通常会产生高毒性。马利巴韦(MBV)是一种新型口服抗病毒药物,因其对脆弱患者具有良好的安全性而闻名。我们描述了一例肾移植后伴有终末器官损伤的 CMV 病例,该病例存在受体-供体血清不匹配的高风险。患者是一名 54 岁的女性,有肥胖、高血压和慢性肾脏病史,2022 年 11 月接受肾移植后服用泼尼松和他克莫司,不久后出现原发性 CMV 感染,接受了缬更昔洛韦和 CMV Ig 治疗。2023 年 1 月,患者出现发热和呼吸困难。CT扫描发现肺部粟粒性不透明和右上叶合并症,BAL和血清中CMV-DNA阳性。肺活检证实了 CMV 感染。抗病毒药物改为更昔洛韦。尽管最初的疗效不错,但 8 天后出现了发热和呼吸衰竭,导致患者在第 15 天插管。由于血清 CMV-DNA 下降缓慢,并且检测到了 UL97 突变,从而对缬更昔洛韦和更昔洛韦产生了耐药性,患者开始服用福斯卡尼和来特莫韦。患者呼吸逐渐好转后拔管,从重症监护室出院到康复科,并伴有 HFNC;记录显示血清 CMV-DNA 下降,但 BAL 上的 CMV-DNA 持续升高。第 8 周时,开始使用 MBV,并继续使用利特莫韦,疗程为 8 周,无明显不良反应。呼吸功能有所改善,但不久后出现了脓毒性休克。骨髓活检结果为淋巴瘤,但无治疗指征:患者出现昏迷,入院 6 个月后死亡。最近,MBV 在欧洲被批准用于治疗造血干细胞移植和 SOT 受者的 R/R CMV。与 SOC 相比,MBV 在 8 周后的病毒血症清除率更高,同时还显示出良好的安全性,中断治疗以及受肾毒性和中性粒细胞减少症影响的患者较少。其主要副作用是味觉障碍、胃肠道症状和气喘。基于抗病毒治疗的实际前景,还需要更多数据来证实 MBV 在毒性方面的益处以及对高度脆弱人群(如 SOT 受者)死亡率的影响。我们对目前有关 MBV 治疗肾移植受者 CMV 感染的文献进行了叙述性综述,以了解 MBV 在这一人群中的临床特点、安全性和疗效。我们在主要科学数据库中进行了检索。共发现 194 篇论文,通过标题和摘要评估排除了其中的 188 篇。随后,我们纳入了 6 篇论文。我们对所有研究对象进行了描述性统计。纳入分析的研究显示,男性受试者的比例较高。年龄中位数为 57 岁。报告最多的合并症是慢性肾功能衰竭。七名患者报告了供体/受体不匹配(D+/R-)。该病例报告和从文献中收集的患者队列显示,MBV 被用作 R/R CMV 的一种选择,特别是在 CMV 对之前的治疗存在或怀疑耐药的情况下。肾脏 SOT 中 CMV 的临床表现多种多样,包括孤立的 CMV DNA 血症再活化、孤立的发热或胃肠道受累。对于轻度至中度 CMV 疾病,如我们的综述中所报告的病例,或已证实对更昔洛韦、福斯卡尼或西多福韦耐药的病例,MBV 可能是一种有价值的选择。所有研究均未报告接受 MBV 治疗的患者的结果;但在报告的病例中,45.4% 的病例在接受 MBV 治疗期间出现病毒学失败,并对 MBV 产生了特异性耐药性。MBV一般耐受性良好,毒性较低,通常是可逆的。引入新的口服抗病毒药物,如MBV,可以改善治疗、预防和先期治疗策略,特别是对有抗CMV治疗经验的患者。
{"title":"Maribavir treatment for resistant cytomegalovirus disseminated disease in kidney transplant recipients: A case-based scoping review of real life data in literature","authors":"","doi":"10.1016/j.trre.2024.100873","DOIUrl":"10.1016/j.trre.2024.100873","url":null,"abstract":"<div><p>The treatment of refractory CMV is often associated with high toxicity. Maribavir (MBV) is a novel oral antiviral, known for its favourable safety profile in fragile patients. We describe a case of CMV disease with end organ damage following kidney transplantation at high risk, for recipient-donor serological mismatch. A 54-year-old female with history of obesity, hypertension, and chronic kidney disease, on prednisone and tacrolimus after kidney transplantation in November 2022, soon after developed primary CMV infection, treated with Valganciclovir and CMV Ig. In January 2023 the patient presented with fever and dyspnea. Pulmonary miliary opacities and right-upper lobe consolidation were found at CT-scan along with CMV-DNA positivity on BAL and serum. Lung biopsy confirmed CMV infection. Antiviral was switched to Ganciclovir. Despite initial benefit, fever and respiratory failure happened 8 days later, leading to intubation at day 15. Due to slow decrease serum CMV-DNA and detection of UL97 mutation, conferring resistance to valganciclovir and ganciclovir, the patient was started on foscarnet and letermovir. She was extubated after a gradual respiratory improvement and discharged from ICU to rehabilitation department with HFNC; reduction in serum CMV-DNA, but persistently elevated CMV-DNA on BAL were documented. At week 8, MBV was started and letermovir continued, for a 8 weeks course, without notable adverse effects. Respiratory function improved but soon after septic shock occurred. A bone marrow biopsy resulted in lymphoma, without indications for treatment: the patient developed coma and died 6 months after admission. MBV has recently been approved in Europe for treatment of R/R CMV in HSCT and SOT recipients. MBV showed superior rates of viraemia clearance after 8 weeks compared to SOC, demonstrating also a favourable safety profile with fewer patients discontinuing treatment and being affected by nephrotoxicity and neutropenia. Its main side effects are taste impairment, gastro-intestinal symptoms and asthenia. Based on actual promising perspectives regarding antiviral stewardship, more data are required to corroborate benefit of MBV in terms of toxicity and impact on mortality in highly fragile populations as SOT recipients.</p><p>MBV received approval for the treatment of refractory or resistant CMV infections to other antiviral agents. Nevertheless, real-life data on efficacy and safety of MBV are still lacking.</p><p>We conducted a narrative review of the current literature on MBV as treatment for CMV infection in kidney transplant recipients to understand clinical characteristics, safety and outcomes of MBV in this population. A search was run on the main scientific databases. 194 papers were identified, of which 188 were excluded by title and abstract evaluation. Subsequently, 6 papers were included. We performed descriptive statistics on the entire study population. The studies included in our analysis showed a higher preva","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142040452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Water/fluid intake in Kıdney transplant recipients: An underrated topic 肾移植受者的水/液体摄入量:一个被低估的话题
IF 3.6 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-08-08 DOI: 10.1016/j.trre.2024.100876

Although kidney transplantation (KT) is the best treatment option for end-stage kidney disease, long-term complications such as chronic kidney allograft dysfunction and cardiovascular disorders are observed. To decrease these complications, preventive measures must be applied in kidney transplant recipients (KTRs). One of these common measures is the increase of water/fluid intake although this is not evidence-based practice. Indeed, surprisingly very limited studies evaluated the impact of increased water/fluid intake on graft function, with small number of KTRs and short term follow-up. We suggest that the water/fluid intake should be personalized based on baseline graft function, time onset after KT (which water homeostasis changes), presence of hyponatremia and hypervolemia, concomitant medications, and patient willingness. Methods for estimating water/fluid intake (direct measurement, 24-h urine volume measurement, urine osmolarity) has both advantages and drawbacks and the best method has not been identified. Increase of water/fluid intake in specific conditions (in hot, and humid weather, before exercise, during Ramadan fasting) or in distinct KTRs (KTRs with de novo nephrolithiasis, frequent urinary tract infections) is not tested. Furthermore, the relationship between water/fluid intake and major cardiovascular adverse events are not known. There is no doubt that minimum amount of water/fluid intake is necessary for graft function (the amount is not known) but there is no evidence for a particular target level of water/fluid intake. In the current review, we summarize the studies assessing fluid/water intake in KTR, explained the pathophysiologic basis of water disorders in early period of KT and late after KT, elucidate conflicts and unknown issues of water intake in KTRs and suggest future research needs.

虽然肾移植(KT)是治疗终末期肾病的最佳方法,但也会出现慢性肾移植功能障碍和心血管疾病等长期并发症。为了减少这些并发症,必须对肾移植受者(KTR)采取预防措施。其中一项常见的措施是增加水/液体的摄入量,但这并非循证实践。事实上,评估增加水/流体摄入量对移植物功能影响的研究非常有限,而且只有少数肾移植受者和短期随访。我们建议,水/液体摄入量应根据基线移植物功能、KT 后的起始时间(水稳态会发生变化)、是否存在低钠血症和高血容量血症、伴随药物以及患者意愿进行个性化调整。估计水/液体摄入量的方法(直接测量、24 小时尿量测量、尿渗透压)既有优点也有缺点,目前尚未确定最佳方法。在特定条件下(炎热潮湿的天气、运动前、斋月禁食期间)或在不同的 KTR(患有新发肾结石、尿路感染频繁的 KTR)中增加水/流体摄入量的方法没有经过测试。此外,水/液体摄入量与主要心血管不良事件之间的关系尚不清楚。毫无疑问,最低限度的水/流体摄入量对移植物功能是必要的(水/流体摄入量尚不清楚),但没有证据表明水/流体摄入量有特定的目标水平。在本综述中,我们总结了评估 KTR 水/液体摄入量的研究,解释了 KT 早期和 KT 后期水失调的病理生理基础,阐明了 KTR 水摄入量的冲突和未知问题,并提出了未来的研究需求。
{"title":"Water/fluid intake in Kıdney transplant recipients: An underrated topic","authors":"","doi":"10.1016/j.trre.2024.100876","DOIUrl":"10.1016/j.trre.2024.100876","url":null,"abstract":"<div><p>Although kidney transplantation (KT) is the best treatment option for end-stage kidney disease, long-term complications such as chronic kidney allograft dysfunction and cardiovascular disorders are observed. To decrease these complications, preventive measures must be applied in kidney transplant recipients (KTRs). One of these common measures is the increase of water/fluid intake although this is not evidence-based practice. Indeed, surprisingly very limited studies evaluated the impact of increased water/fluid intake on graft function, with small number of KTRs and short term follow-up. We suggest that the water/fluid intake should be personalized based on baseline graft function, time onset after KT (which water homeostasis changes), presence of hyponatremia and hypervolemia, concomitant medications, and patient willingness. Methods for estimating water/fluid intake (direct measurement, 24-h urine volume measurement, urine osmolarity) has both advantages and drawbacks and the best method has not been identified. Increase of water/fluid intake in specific conditions (in hot, and humid weather, before exercise, during Ramadan fasting) or in distinct KTRs (KTRs with de novo nephrolithiasis, frequent urinary tract infections) is not tested. Furthermore, the relationship between water/fluid intake and major cardiovascular adverse events are not known. There is no doubt that minimum amount of water/fluid intake is necessary for graft function (the amount is not known) but there is no evidence for a particular target level of water/fluid intake. In the current review, we summarize the studies assessing fluid/water intake in KTR, explained the pathophysiologic basis of water disorders in early period of KT and late after KT, elucidate conflicts and unknown issues of water intake in KTRs and suggest future research needs.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142011599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Methods to prevent lymphocele after kidney transplantation: Seeking the optimal technique for avoiding a preventable complication 预防肾移植术后淋巴结肿大的方法:寻求避免可预防并发症的最佳技术
IF 3.6 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-08-07 DOI: 10.1016/j.trre.2024.100877

Background

There are multiple methods for preventing lymphocele formation after kidney transplantation (KTx). However, lymphoceles still develop in up to one third of patients and the effectiveness of these different methods in preventing lymphocele is not well described. Here, we summarize the current strategies for preventing lymphocele after KTx.

Methods

We conducted searches across several literature databases, including Medline (via PubMed), Web of Science, EMBASE, and Cochrane Central. Lymphocele formation after KTx was the outcome of interest. A random-effects model was applied to evaluate pooled estimates, which were presented as hazard ratios (HRs) and odds ratios (ORs), along with the random pooled estimate (ES), 95% confidence interval (95% CI), and P value. We calculated the pooled rate of lymphocele formation after KTx with the following preventive methods: LigaSure, haemostatic materials, prophylactic drainage, ligation, peritoneal fenestration, and bipolar cautery techniques.

Results

The literature search retrieved 87 unique studies after excluding duplicates. Twenty papers reporting on 5445 patients were incorporated in the qualitative analysis. The pooled lymphocele rate was 3.0% (95% CI = 0.6–13.7) for the LigaSure method, 8.3% (95% CI = 6.4–10.7) for drainage, 9.2% (95% CI = 5.9–14.1) for haemostatic materials, 12.2% (95% CI = 9.2–16.1) for ligation, 14.4% (95% CI = 12.0–17.3) for peritoneal fenestration, and 20.5% (95% CI = 10.2–36.8) for bipolar sealing.

Conclusion

Despite preventive methods, the incidence of lymphocele following KTx remains high. The use of LigaSure appears to be the most effective method for preventing lymphocele. However, given the broad range of reported lymphocele rates and lack of control groups, further validation of these findings is necessary.

背景有多种方法可预防肾移植(KTx)后淋巴结的形成。然而,仍有多达三分之一的患者会出现淋巴结肿大,而这些不同方法在预防淋巴结肿大方面的效果却没有得到很好的描述。我们在多个文献数据库中进行了检索,包括 Medline(通过 PubMed)、Web of Science、EMBASE 和 Cochrane Central。KTx术后淋巴囊形成是我们关注的结果。采用随机效应模型评估汇总估计值,以危险比(HR)和几率比(OR)以及随机汇总估计值(ES)、95% 置信区间(95% CI)和 P 值表示。我们计算了采用以下预防方法进行 KTx 后淋巴囊形成的汇总率:结果文献检索在排除重复后检索到 87 篇研究。定性分析纳入了 20 篇报告 5445 名患者的论文。LigaSure方法的汇总淋巴囊肿率为3.0% (95% CI = 0.6-13.7),引流为8.3% (95% CI = 6.4-10.7),止血材料为9.2% (95% CI = 5.9-14.1),结扎为12.2% (95% CI = 9.2-16.1)。结论尽管采用了预防方法,但 KTx 术后淋巴结肿大的发生率仍然很高。使用 LigaSure 似乎是预防淋巴结肿大最有效的方法。然而,由于报告的淋巴囊肿发生率范围很广,而且缺乏对照组,因此有必要进一步验证这些研究结果。
{"title":"Methods to prevent lymphocele after kidney transplantation: Seeking the optimal technique for avoiding a preventable complication","authors":"","doi":"10.1016/j.trre.2024.100877","DOIUrl":"10.1016/j.trre.2024.100877","url":null,"abstract":"<div><h3>Background</h3><p>There are multiple methods for preventing lymphocele formation after kidney transplantation (KTx). However, lymphoceles still develop in up to one third of patients and the effectiveness of these different methods in preventing lymphocele is not well described. Here, we summarize the current strategies for preventing lymphocele after KTx.</p></div><div><h3>Methods</h3><p>We conducted searches across several literature databases, including Medline (<em>via</em> PubMed), Web of Science, EMBASE, and Cochrane Central. Lymphocele formation after KTx was the outcome of interest. A random-effects model was applied to evaluate pooled estimates, which were presented as hazard ratios (HRs) and odds ratios (ORs), along with the random pooled estimate (ES), 95% confidence interval (95% CI), and <em>P</em> value. We calculated the pooled rate of lymphocele formation after KTx with the following preventive methods: LigaSure, haemostatic materials, prophylactic drainage, ligation, peritoneal fenestration, and bipolar cautery techniques.</p></div><div><h3>Results</h3><p>The literature search retrieved 87 unique studies after excluding duplicates. Twenty papers reporting on 5445 patients were incorporated in the qualitative analysis. The pooled lymphocele rate was 3.0% (95% CI = 0.6–13.7) for the LigaSure method, 8.3% (95% CI = 6.4–10.7) for drainage, 9.2% (95% CI = 5.9–14.1) for haemostatic materials, 12.2% (95% CI = 9.2–16.1) for ligation, 14.4% (95% CI = 12.0–17.3) for peritoneal fenestration, and 20.5% (95% CI = 10.2–36.8) for bipolar sealing.</p></div><div><h3>Conclusion</h3><p>Despite preventive methods, the incidence of lymphocele following KTx remains high. The use of LigaSure appears to be the most effective method for preventing lymphocele. However, given the broad range of reported lymphocele rates and lack of control groups, further validation of these findings is necessary.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0955470X24000600/pdfft?md5=b0422cadf57c41c58fd407623b230a04&pid=1-s2.0-S0955470X24000600-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141978246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of cytomegalovirus in adult solid organ transplant patients: GESITRA-IC-SEIMC, CIBERINFEC, and SET recommendations update 成人实体器官移植患者巨细胞病毒的管理:GESITRA-IC-SEIMC、CIBERINFEC 和 SET 建议更新
IF 3.6 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-08-05 DOI: 10.1016/j.trre.2024.100875

Cytomegalovirus (CMV) infection remains a significant challenge in solid organ transplantation (SOT). The last international consensus guidelines on the management of CMV in SOT were published in 2018, highlighting the need for revision to incorporate recent advances, notably in cell-mediated immunity monitoring, which could alter the current standard of care. A working group including members from the Group for the Study of Infection in Transplantation and the Immunocompromised Host (GESITRA-IC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Society of Transplantation (SET), developed consensus-based recommendations for managing CMV infection in SOT recipients. Recommendations were classified based on evidence strength and quality using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. The final recommendations were endorsed through a consensus meeting and approved by the expert panel.

巨细胞病毒(CMV)感染仍是实体器官移植(SOT)中的一项重大挑战。上一份关于SOT中CMV管理的国际共识指南于2018年发布,强调了修订的必要性,以纳入最新进展,特别是细胞介导免疫监测方面的进展,这可能会改变当前的护理标准。一个包括西班牙传染病和临床微生物学学会(SEIMC)移植和免疫功能低下宿主感染研究小组(GESITRA-IC)和西班牙移植学会(SET)成员在内的工作组,为管理 SOT 受者中的 CMV 感染制定了基于共识的建议。根据证据强度和质量,采用建议评估、发展和评价分级 (GRADE) 系统对建议进行了分类。最终建议通过共识会议获得认可,并由专家小组批准。
{"title":"Management of cytomegalovirus in adult solid organ transplant patients: GESITRA-IC-SEIMC, CIBERINFEC, and SET recommendations update","authors":"","doi":"10.1016/j.trre.2024.100875","DOIUrl":"10.1016/j.trre.2024.100875","url":null,"abstract":"<div><p>Cytomegalovirus (CMV) infection remains a significant challenge in solid organ transplantation (SOT). The last international consensus guidelines on the management of CMV in SOT were published in 2018, highlighting the need for revision to incorporate recent advances, notably in cell-mediated immunity monitoring, which could alter the current standard of care. A working group including members from the Group for the Study of Infection in Transplantation and the Immunocompromised Host (GESITRA-IC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Society of Transplantation (SET), developed consensus-based recommendations for managing CMV infection in SOT recipients. Recommendations were classified based on evidence strength and quality using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. The final recommendations were endorsed through a consensus meeting and approved by the expert panel.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0955470X24000582/pdfft?md5=921bac6bf46668e5dd82f84cf79a56a2&pid=1-s2.0-S0955470X24000582-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142011598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Barriers and facilitators of deceased organ donation among Muslims living globally: An integrative systematic review 全球穆斯林进行已故器官捐赠的障碍和促进因素:综合系统综述。
IF 3.6 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-07-31 DOI: 10.1016/j.trre.2024.100874

Aim

To identify the barriers and facilitators of deceased organ donation among the Muslim community living globally.

Method

A systematic search was undertaken in databases such as CINAHL, Medline with full text, Global Health and PsycINFO via EBSCO; Scopus via Elsevier; Web of Science via Clarivate; and PubMed via US National Library of Medicine National Institute of Health were used to retrieve the studies on the 31st of December 2023. Apart from these databases two other journals, the Saudi Journal of Kidney Diseases and Transplantation, and the Journal of Experimental and Clinical Transplantation were also used to search for relevant studies. Quantitative and qualitative studies that addressed the aim of the present review published from the 30th of April 2008 were included.

Results

Of the 10,474 studies, 95 studies were included in the review. The following five themes were generated based on narrative synthesis: 1) knowledge of organ donation, 2) willingness to donate, 3) community influence, 4) bodily influence, and 5) religious influence. While individuals view organ donation as a noble act, societal influences significantly impact their decision to register. Concerns include religious permissibility, potential misuse for commercial purposes, and the dignity and respect given to the deceased donor's body.

Conclusions

This review finds deceased organ donation decisions in this population are collective, influenced by religious views, and hindered by uncertainty. Interventional studies on strategies to address uncertainty could help us identify best practices for this population to improve deceased organ donation. Rather than an individual approach among this population, a whole-system approach, tailored-made evidence-guided community engagement could improve donation rates.

目的:确定全球穆斯林群体中已故器官捐赠的障碍和促进因素:在 EBSCO 的 CINAHL、Medline 全文、Global Health 和 PsycINFO;Elsevier 的 Scopus;Clarivate 的 Web of Science;以及美国国家医学图书馆国家健康研究所的 PubMed 等数据库中进行了系统搜索,以检索截至 2023 年 12 月 31 日的研究。除这些数据库外,还使用了另外两个期刊,即《沙特肾脏疾病与移植期刊》和《实验与临床移植期刊》来搜索相关研究。2008年4月30日以来发表的与本综述目的相关的定量和定性研究均被纳入其中:结果:在 10,474 项研究中,有 95 项研究被纳入综述。根据叙事综合得出以下五个主题:1)器官捐献知识;2)捐献意愿;3)社区影响;4)身体影响;5)宗教影响。虽然个人认为器官捐献是一种高尚的行为,但社会影响对他们登记的决定产生了重大影响。关注的问题包括宗教允许性、出于商业目的的潜在滥用,以及给予已故捐赠者身体的尊严和尊重:本综述发现,在这一人群中,已故器官捐献决定是集体性的,受到宗教观点的影响,并受到不确定性的阻碍。对解决不确定性的策略进行干预性研究可帮助我们确定适用于这一人群的最佳做法,以改善已故器官捐献。与其在这一人群中采取单独的方法,不如采取全系统的方法,通过量身定制的、以证据为指导的社区参与来提高捐献率。
{"title":"Barriers and facilitators of deceased organ donation among Muslims living globally: An integrative systematic review","authors":"","doi":"10.1016/j.trre.2024.100874","DOIUrl":"10.1016/j.trre.2024.100874","url":null,"abstract":"<div><h3>Aim</h3><p>To identify the barriers and facilitators of deceased organ donation among the Muslim community living globally.</p></div><div><h3>Method</h3><p>A systematic search was undertaken in databases such as CINAHL, Medline with full text, Global Health and PsycINFO via EBSCO; Scopus via Elsevier; Web of Science via Clarivate; and PubMed via US National Library of Medicine National Institute of Health were used to retrieve the studies on the 31st of December 2023. Apart from these databases two other journals, the Saudi Journal of Kidney Diseases and Transplantation, and the Journal of Experimental and Clinical Transplantation were also used to search for relevant studies. Quantitative and qualitative studies that addressed the aim of the present review published from the 30th of April 2008 were included.</p></div><div><h3>Results</h3><p>Of the 10,474 studies, 95 studies were included in the review. The following five themes were generated based on narrative synthesis: 1) knowledge of organ donation, 2) willingness to donate, 3) community influence, 4) bodily influence, and 5) religious influence. While individuals view organ donation as a noble act, societal influences significantly impact their decision to register. Concerns include religious permissibility, potential misuse for commercial purposes, and the dignity and respect given to the deceased donor's body.</p></div><div><h3>Conclusions</h3><p>This review finds deceased organ donation decisions in this population are collective, influenced by religious views, and hindered by uncertainty. Interventional studies on strategies to address uncertainty could help us identify best practices for this population to improve deceased organ donation. Rather than an individual approach among this population, a whole-system approach, tailored-made evidence-guided community engagement could improve donation rates.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0955470X24000570/pdfft?md5=17dfd1c068f85138d6c7e54e7dcb56f3&pid=1-s2.0-S0955470X24000570-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141879962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Measuring patient-reported experience of solid organ transplantation healthcare: A scoping review of condition- and transplant-specific measures 测量患者报告的实体器官移植医疗体验:针对特定条件和移植的衡量标准的范围界定审查
IF 3.6 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-07-15 DOI: 10.1016/j.trre.2024.100872

Background

Measures of patient experience are increasingly valued as key to healthcare quality assessment. We aimed to identify and describe publicly available measures assessing patient-reported experience of solid organ transplantation healthcare, and identify patient groups, healthcare settings, or aspects of patient experience underserved by existing measures.

Methods

We systematically searched MEDLINE, Embase, CINAHL, PsycINFO, Cochrane CENTRAL, Scopus and Web of Science from inception to 6th July 2023; supplemented with grey literature searches. Two reviewers independently screened search hits; outputs reporting patient-reported measures of multiple aspects of established solid organ transplantation healthcare were eligible. We abstracted measure context, characteristics, content (i.e., attributes of patient experience assessed), and development and validation processes.

Results

We identified nine outputs reporting eight measures of patient experience; these related only to kidney (n = 5) or liver (n = 3) transplantation, with no available measures relating to heart, lung, pancreas or intestinal transplantation. Of the identified measures, four were specific to solid organ transplant recipients. Measures sought to assess “patient satisfaction” (n = 4) and “patient experience” (n = 4) of healthcare. Measures mapped to between five and 16 of 20 attributes of patient experience, most often Information and education, Communication, and Access to care (all n = 7). Six measures reported a development process, only three reported a validation process.

Conclusions

Publicly available patient-reported measures of organ transplantation healthcare experiences are limited to kidney and liver transplantation. There is heterogeneity in measure context, characteristics, and content, and insufficient clarity concerning how well measures capture the specific experiences of transplant recipients. Formalised measures of patient experience, specific to solid organ transplantation, with transparent reporting of development and validity are needed.

背景患者体验评估作为医疗质量评估的关键日益受到重视。我们旨在确定并描述评估患者报告的实体器官移植医疗体验的公开可用措施,并确定现有措施未充分服务的患者群体、医疗环境或患者体验的各个方面。方法我们系统地检索了从开始到 2023 年 7 月 6 日的 MEDLINE、Embase、CINAHL、PsycINFO、Cochrane CENTRAL、Scopus 和 Web of Science;并辅以灰色文献检索。两名审稿人分别独立筛选检索结果;符合条件的结果报告了患者报告的对已建立的实体器官移植医疗保健的多个方面的测量结果。我们摘录了衡量标准的背景、特征、内容(即评估的患者体验属性)以及开发和验证过程。结果我们确定了九项成果,报告了八项患者体验衡量标准;这些衡量标准仅与肾脏(5 项)或肝脏(3 项)移植有关,没有与心脏、肺、胰腺或肠道移植有关的可用衡量标准。在已确定的衡量标准中,有四项专门针对实体器官移植受者。措施旨在评估医疗保健的 "患者满意度"(4 项)和 "患者体验"(4 项)。在患者体验的 20 项属性中,有 5 至 16 项与之对应,最常见的是信息与教育、沟通和获得护理(均为 7 项)。六项措施报告了开发过程,只有三项报告了验证过程。在衡量标准的背景、特征和内容方面存在差异,在衡量标准如何反映器官移植受者的具体经历方面也不够明确。我们需要针对实体器官移植对患者体验进行正式测量,并对开发和有效性进行透明报告。
{"title":"Measuring patient-reported experience of solid organ transplantation healthcare: A scoping review of condition- and transplant-specific measures","authors":"","doi":"10.1016/j.trre.2024.100872","DOIUrl":"10.1016/j.trre.2024.100872","url":null,"abstract":"<div><h3>Background</h3><p>Measures of patient experience are increasingly valued as key to healthcare quality assessment. We aimed to identify and describe publicly available measures assessing patient-reported experience of solid organ transplantation healthcare, and identify patient groups, healthcare settings, or aspects of patient experience underserved by existing measures.</p></div><div><h3>Methods</h3><p>We systematically searched MEDLINE, Embase, CINAHL, PsycINFO, Cochrane CENTRAL, Scopus and Web of Science from inception to 6th July 2023; supplemented with grey literature searches. Two reviewers independently screened search hits; outputs reporting patient-reported measures of multiple aspects of established solid organ transplantation healthcare were eligible. We abstracted measure context, characteristics, content (i.e., attributes of patient experience assessed), and development and validation processes.</p></div><div><h3>Results</h3><p>We identified nine outputs reporting eight measures of patient experience; these related only to kidney (<em>n</em> = 5) or liver (<em>n</em> = 3) transplantation, with no available measures relating to heart, lung, pancreas or intestinal transplantation. Of the identified measures, four were specific to solid organ transplant recipients. Measures sought to assess “patient satisfaction” (<em>n</em> = 4) and “patient experience” (n = 4) of healthcare. Measures mapped to between five and 16 of 20 attributes of patient experience, most often <em>Information and education</em>, <em>Communication,</em> and <em>Access to care</em> (all <em>n</em> = 7). Six measures reported a development process, only three reported a validation process.</p></div><div><h3>Conclusions</h3><p>Publicly available patient-reported measures of organ transplantation healthcare experiences are limited to kidney and liver transplantation. There is heterogeneity in measure context, characteristics, and content, and insufficient clarity concerning how well measures capture the specific experiences of transplant recipients. Formalised measures of patient experience, specific to solid organ transplantation, with transparent reporting of development and validity are needed.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0955470X24000557/pdfft?md5=7aff97411bd1a3e8379bb5a877323594&pid=1-s2.0-S0955470X24000557-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141689867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Simultaneous combined transplantation: Intricacies in immunosuppression management 同步联合移植:免疫抑制管理的复杂性
IF 3.6 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-07-14 DOI: 10.1016/j.trre.2024.100871

Simultaneous combined transplantation (SCT), i.e. the transplantation of two solid organs within the same procedure, can be required when the patients develop more than one end-stage organ failure. The development of SCT over the last 20 years could only be possible thanks to progress in the surgical techniques and in the perioperative management of patients in an ageing population. Performing such major transplant surgeries from the same donor, in a short amount of time, and in critical pathophysiological conditions, is often considered to be counterbalanced by the immune benefits expected from these interventions. However, SCT includes a wide array of different transplant combinations, with each time a different immunological constellation. Recent research offers new insights into the immune mechanisms involved in these different settings. Progress in the understanding of these immunological intricacies help to address the optimal induction and maintenance immunosuppressive treatment strategies. In this review, we summarize the different immunological benefits according to the type of SCT performed. We also incorporate the main outcomes according to the immunological risk at transplantation, and the deleterious impact of preformed or de novo donor-specific antibodies (DSA) in the different types of SCT. Finally, we propose comprehensive and evidence-based induction and maintenance immunosuppression strategies guided by the type of SCT.

同步联合移植(SCT),即在同一手术过程中移植两个实体器官,当患者出现一个以上终末期器官衰竭时就需要进行同步联合移植。在过去的 20 年中,同步联合移植手术的发展得益于外科技术的进步以及对老龄化人群患者围手术期管理的进步。在短时间内,在关键的病理生理条件下,从同一供体进行如此重大的移植手术,通常被认为可以抵消这些干预措施预期带来的免疫益处。然而,SCT 包括多种不同的移植组合,每次都有不同的免疫组合。最近的研究为了解这些不同情况下的免疫机制提供了新的视角。对这些错综复杂的免疫机制的认识取得进展,有助于制定最佳的诱导和维持性免疫抑制治疗策略。在这篇综述中,我们根据所实施的 SCT 类型总结了不同的免疫学益处。我们还根据移植时的免疫风险和不同类型 SCT 中预先形成或从头产生的供体特异性抗体(DSA)的有害影响纳入了主要结果。最后,我们根据 SCT 的类型提出了全面、循证的诱导和维持免疫抑制策略。
{"title":"Simultaneous combined transplantation: Intricacies in immunosuppression management","authors":"","doi":"10.1016/j.trre.2024.100871","DOIUrl":"10.1016/j.trre.2024.100871","url":null,"abstract":"<div><p>Simultaneous combined transplantation (SCT), i.e. the transplantation of two solid organs within the same procedure, can be required when the patients develop more than one end-stage organ failure. The development of SCT over the last 20 years could only be possible thanks to progress in the surgical techniques and in the perioperative management of patients in an ageing population. Performing such major transplant surgeries from the same donor, in a short amount of time, and in critical pathophysiological conditions, is often considered to be counterbalanced by the immune benefits expected from these interventions. However, SCT includes a wide array of different transplant combinations, with each time a different immunological constellation. Recent research offers new insights into the immune mechanisms involved in these different settings. Progress in the understanding of these immunological intricacies help to address the optimal induction and maintenance immunosuppressive treatment strategies. In this review, we summarize the different immunological benefits according to the type of SCT performed. We also incorporate the main outcomes according to the immunological risk at transplantation, and the deleterious impact of preformed or de novo donor-specific antibodies (DSA) in the different types of SCT. Finally, we propose comprehensive and evidence-based induction and maintenance immunosuppression strategies guided by the type of SCT.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141694442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Transplantation Reviews
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1